UK doctors urged to use preventative breast cancer drugs

Hundreds of thousands of women at high risk of developing breast cancer in Britain should be given drugs which could dramatically reduce their chances of getting the disease, doctors were advised Tuesday.

In guidelines issued by the National Institute for Health and Care Excellence (Nice), up to half-a-million women with a family history of the illness should receive the £120 ($185, 141 euros), five-year course of or raloxifene.

The "one-a-day" programme is an alternative to the surgery chosen by celebrities including and Sharon Osbourne, said Nice.

Tamoxifen was shown in a clinical trial to reduce the risk of developing by about 50 percent in high-risk post-menopausal women.

Another trial found raloxifene reduced the risk by around 38 percent although neither drug is currently licensed as a in Britain.

"Tamoxifen is extremely cost effective, that's because it's extremely cheap... and treating someone with costs many thousands of pounds," explained professor Gareth Evans, who helped to develop the guidelines.

"So this treatment is potentially not just cost-effective but cost saving to the NHS and more importantly for women, they don't have to go through the stress and trauma of a diagnosis, radiotherapy, potentially chemotherapy.

"So it's a major breakthrough for women that they are going to be able to be offered this treatment in the future," he added.

campaigners praised the report.

"We believe that this guideline is a game changer for people with a family history of breast cancer," said Caitlin Palframan, assistant head of policy at Breakthrough Breast Cancer.

"In fact for breast cancer overall it's a historic step for prevention.

"We think more women will have more options to reduce their risk, which ultimately means we will prevent more breast cancer cases."

Around 50,000 women and 400 men develop breast cancer every year in Britain, according to Nice figures.

add to favorites email to friend print save as pdf

Related Stories

Study confirms long term benefits of tamoxifen

Jun 03, 2013

(Medical Xpress)—Taking tamoxifen for 10 rather than five years halves the risk of women dying from the most common kind of breast cancer, according to new research being presented at this year's ASCO conference. ...

Recommended for you

US OKs first-ever DNA alternative to Pap smear (Update 2)

11 hours ago

U.S. government health regulators have cleared a genetic test from Roche as a first-choice screening option for cervical cancer. It was a role previously reserved for the Pap smear, the decades-old mainstay of women's health.

New breast cancer imaging method promising

16 hours ago

The new PAMmography method for imaging breast cancer developed by the University of Twente's MIRA research institute and the Medisch Spectrum Twente hospital appears to be a promising new method that could ...

Palliation is rarely a topic in studies on advanced cancer

17 hours ago

End-of-life aspects, the corresponding terminology, and the relevance of palliation in advanced cancer are often not considered in publications on randomized controlled trials (RCTs). This is the result of an analysis by ...

User comments